Article

Ruboxistaurin results: Eli Lilly plans more trials

Indianapolis-Eli Lilly and Co. will delay the submission of its ruboxistaurin for the treatment of diabetic retinopathy and diabetic macular edema (DME) after two clinical trials failed to achieve satisfactory results on disease progression.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
Related Content
Glaucoma Research Foundation announces 2025 recipients of Shaffer Research Grants
March 23rd 2025

Glaucoma Research Foundation announces 2025 recipients of Shaffer Research Grants

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Kalaris and AlloVir Inc. complete merger
March 22nd 2025

Kalaris and AlloVir Inc. complete merger

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

(Image credit: AdobeStock/Atif)
March 21st 2025

Staying the course in shifting winds

Iantrek announces positive 2-year results from clinical study of its bio-interventional platform for uveoscleral outflow enhancement
March 21st 2025

Iantrek announces positive 2-year results from clinical study of its bio-interventional platform for uveoscleral outflow enhancement

© 2025 MJH Life Sciences

All rights reserved.